Afrezza Sale, or Afrezza Sales ??

[mnholdem]

One could arguably state that MannKind is actually in a better position today than they were immediately prior to signing with Sanofi in August-2014.

While some may argue that there was a paltry amount of marketing, MannKind Corporation paid its 35% share of the marketing costs and therefore is entitled to all marketing materials that have been designed and printed by Sanofi to date WITHOUT having to pay anything more.  I, myself, received one of those direct-to-consumer mailings (you may recall that I posted a video of me opening the contents). Any and all Afrezza marketing (TV, web, print, etc.) that has been designed and paid for to date will now belong to MannKind Corporation, including the Afrezza and Afrezza-Pro websites. Some of the material developed by Sanofi was, in my opinion, pretty lame advertising but management would be foolish to toss any printed materials in the trash.

It will take only a few regional partnerships outside the U.S. to immediately change the cash position of this company, so I do not agree with anyone who claims that the situation has become so dire that MannKind must put the company up for sale.

I have built two companies (from startup to becoming internationally competitive) during my career and I can tell you emphatically that MannKind is a long ways from having to consider putting itself up for sale in order to avoid bankruptcy. There have been some biotechs companies that have used creative ways to secure cash, such as royalty-base financing where the bank receives a royalty of future sales of one or more drugs in exchange for financing the development. I consider this approach as somewhat last resort, however. There are other ways to extend the cash runway.  Obviously, upfront payments on collaborations is a preferred strategy.

Is there interest? Absolutely! I think CEO Pfeffer would not be so irresponsible and reckless as to lie by fabricating a story that two drug distribution companies contacted MannKind within 24 hours of Sanofi's termination notice to resume talks related to distribution of Afrezza outside the U.S. In light of the CEO's comment, it completely baffles me how certain posters still insist that there is no interest in Afrezza or in the company.   

---

I'm of the opinion that MannKind should not sell Afrezza unless they receive an offer that meets what they KNOW that it's worth. Until they receive such an offer, management should license Afrezza worldwide through partner(s) who do not have a conflict of interest within their drug portfolios.

Even though you may be tired of hearing me say it, I think that early intensive insulin therapy with Afrezza monomer insulin will result in 40%-60% drug-free remission of diabetes mellitus if the therapy is applied soon enough to halt irreparable damage to the pancreas. Once this is proven and accepted by the medical community, Afrezza may be able to command a premium. But that is several years and trials down the road. In the meantime, there is a robust market among diabetic patients who lack control of their glucose levels. There remains, of course, the needle-phobic population but needle-free delivery of insulin is not the primary benefit here.

Afrezza can become a blockbuster drug, not just by becoming the new standard of first treatment in the fight against this disease, but by combining with a yet-to-be-marketed low-cost Blood Glucose Monitor which, when used in combination with Afrezza, will lead to unprecedented CONTROL of blood glocuse levels and the virtually elimination of the physiological damage caused by diabetes mellitus.

---

 MannKind Corporation is still owner of a disruptive medical treatment - perhaps Al Mann's greatest achievement - and evidence continues to mount that Afrezza monomer insulin offers tremendous results when administered correctly. 

As I stated above, I think that MannKind Corporation is in a better position than it was immediately prior to signing the LC&A with Sanofi. After what happened with Sanofi, management is also wiser about who they should partner with, as well as the terms they will agree to.

[cjc04]

reading this thread is frustrating.......

So far, MNKD has signed the worst deal possible to promote Afrezza that completely screwed the company, and let's not forget that they AGREED to have their mouths taped shut the entire time they were being screwed.

They mishandled the debt refinancing about as bad as could possibly be mishandled.

Look like foolish amatures for the results of the TASE listing.

Appointed and allowed bumbling Hakan to control things thru all of this..... Boy, it must have difficult for SNY to get things past him.

Again, appear as foolish amatures for the handling of their CEO position from Hakan to now.

AND SOME OF YOU WANT MNKD TO TAKE ON BIG PHARMA ALONE? IN ONE OF THE MOST CUT THROAT SECTORS, DIABETES? WITH A DISTRUPTIVE PRODUCT??

MNKD has NO MONEY!!!! NO LEADERSHIP!!!! NO INFLUENCE ON DOCS!!!!

Whether or not this magical proposal is even remotely possible, I don't think I'm willing to watch this self-destruction any longer.

IT MUST BE SOLD NOW!!!!!!

imo, the best thing we could hope for is that the BP's know how good Afrezza is and there really is some kind behind the scenes bidding going on.

[cjc04]

Mar 10, 2016 9:03:53 GMT -5 mnholdem said:

One could arguably state that MannKind is actually in a better position today than they were immediately prior to signing with Sanofi in August-2014.

While some may argue that there was a paltry amount of marketing, MannKind Corporation paid its 35% share of the marketing costs and therefore is entitled to all marketing materials that have been designed and printed by Sanofi to date WITHOUT having to pay anything more.  I, myself, received one of those direct-to-consumer mailings (you may recall that I posted a video of me opening the contents). Any and all Afrezza marketing (TV, web, print, etc.) that has been designed and paid for to date will now belong to MannKind Corporation, including the Afrezza and Afrezza-Pro websites. Some of the material developed by Sanofi was, in my opinion, pretty lame advertising but management would be foolish to toss any printed materials in the trash.

It will take only a few regional partnerships outside the U.S. to immediately change the cash position of this company, so I do not agree with anyone who claims that the situation has become so dire that MannKind must put the company up for sale.

I have built two companies (from startup to becoming internationally competitive) during my career and I can tell you emphatically that MannKind is a long ways from having to consider putting itself up for sale in order to avoid bankruptcy. There have been some biotechs companies that have used creative ways to secure cash, such as royalty-base financing where the bank receives a royalty of future sales of one or more drugs in exchange for financing the development. I consider this approach as somewhat last resort, however. There are other ways to extend the cash runway.  Obviously, upfront payments on collaborations is a preferred strategy.

Is there interest? Absolutely! I think CEO Pfeffer would not be so irresponsible and reckless as to lie by fabricating a story that two drug distribution companies contacted MannKind within 24 hours of Sanofi's termination notice to resume talks related to distribution of Afrezza outside the U.S. In light of the CEO's comment, it completely baffles me how certain posters still insist that there is no interest in Afrezza or in the company.   

---

I'm of the opinion that MannKind should not sell Afrezza unless they receive an offer that meets what they KNOW that it's worth. Until they receive such an offer, management should license Afrezza worldwide through partner(s) who do not have a conflict of interest within their drug portfolios.

Even though you may be tired of hearing me say it, I think that early intensive insulin therapy with Afrezza monomer insulin will result in 40%-60% drug-free remission of diabetes mellitus if the therapy is applied soon enough to halt irreparable damage to the pancreas. Once this is proven and accepted by the medical community, Afrezza may be able to command a premium. But that is several years down the road.

Afrezza can become blockbuster drug, not just by becoming the new standard of first treatment in the fight against this disease, but by combining with a yet-to-be-marketed low-cost Blood Glucose Monitor which, when used in combination with Afrezza, will lead to unprecedented CONTROL of blood glocuse levels and the virtually elimination of the physiological damage caused by diabetes mellitus.

---

 MannKind Corporation is still owner of a disruptive medical treatment - perhaps Al Mann's greatest achievement - and evidence continues to mount that Afrezza monomer insulin offers tremendous results when administered correctly. 

As I stated above, I think that MannKind Corporation is in a better position than it was immediately prior to signing the LC&A with Sanofi. After what happened with Sanofi, management is also wiser about who they should partner with, as well as the terms they will agree to.

Sorry MN,,,, I couldn't get past the 1st paragraph..... All the marketing materials have SANOFI's name on them, they're useless.

[dictatorsaurus]

Mar 10, 2016 9:24:01 GMT -5 cjc04 said:

reading this thread is frustrating.......

So far, MNKD has signed the worst deal possible to promote Afrezza that completely screwed the company, and let's not forget that they AGREED to have their mouths taped shut the entire time they were being screwed.

They mishandled the debt refinancing about as bad as could possibly be mishandled.

Look like foolish amatures for the results of the TASE listing.

Appointed and allowed bumbling Hakan to control things thru all of this..... Boy, it must have difficult for SNY to get things past him.

Again, appear as foolish amatures for the handling of their CEO position from Hakan to now.

AND SOME OF YOU WANT MNKD TO TAKE ON BIG PHARMA ALONE? IN ONE OF THE MOST CUT THROAT SECTORS, DIABETES? WITH A DISTRUPTIVE PRODUCT??

MNKD has NO MONEY!!!! NO LEADERSHIP!!!! NO INFLUENCE ON DOCS!!!!

Whether or not this magical proposal is even remotely possible, I don't think I'm willing to watch this self-destruction any longer.

IT MUST BE SOLD NOW!!!!!!

imo, the best thing we could hope for is that the BP's know how good Afrezza is and there really is some kind behind the scenes bidding going on.

I agree. MNKD/Afrezza must be sold and must be sold soon. Even the cash issue has not been addressed yet and we are running out of time.

[monger]

Mar 10, 2016 9:25:59 GMT -5 cjc04 said:

Mar 10, 2016 9:03:53 GMT -5 mnholdem said:

Some of the material developed by Sanofi was, in my opinion, pretty lame advertising but management would be foolish to toss any printed materials in the trash.

Sorry MN,,,, I couldn't get past the 1st paragraph..... All the marketing materials have SANOFI's name on them, they're useless.

Well, let's assume that MN didn't actually mean keep the printed materials, but was referring to the design files underlying the material.  Otherwise, in addition to his other duties, Matt is going to be sitting around pasting MannKind stickers over the Sanofi logo.  :-)  Besides, Sanofi probably only printed 200 brochures, handed out half of them, and called it a day.

On a more serious note, given that the mandatory labeling is poor, docs either haven't heard of Afrezza or aren't interested, and the general public is mostly unaware of it, I question whether any of the current material is even appropriate for the new kind of marketing that MNKD needs to do.  I'm thinking that the clinics may be a really brilliant move in that they can see to it that patients get the right information, and use Afrezza the right way.  Once that's successful and there is a growing body of documentation, plus social media, about how this is working, we can expect different results.  IOW, not only will we see some modest script increases from a few clinics, which in themselves are not going to right the ship, but there will be evidence that can be presented to other doctors (but maybe not by MNKD directly) about how this is working in the real world.  I think it's just a matter of getting the docs' attention with MANY real results, like hundreds if not thousands.  I don't think other docs are going to be threatened by the growth of these clinics, but I do think they'll pay attention to the science once there's sufficient real world data.

Probably a better plan than pasting stickers on brochures...